{"denoms":[{"counts":[{"groupId":"BG000","value":"3"}],"units":"Participants"}],"groups":[{"description":"Daily alternating thalidomide and lenalidomide plus rituximab (ThRiL) in patients with previously treated WM\n\nThalidomide: Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 \\& 27)\n\nLenalidomide: Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 \\& 28). Lenalidomide will be initiated at a starting dose of 5 mg.\n\nRituximab: Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).","id":"BG000","title":"All Patients"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"50-59"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"60-69"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"80-89"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}